TEST:

PGDx elio™ tissue complete assay

PGDx elio™ tissue complete is a comprehensive, in-vitro diagnostic, next generation sequencing (NGS) assay that identifies key genomic alterations and guideline supported biomarkers in solid tumors using a 500+ gene panel. PGDx elio™ tissue complete is the industry’s first and only NGS diagnostic kit for comprehensive tumor profiling that is FDA-cleared for use in labs across the country. This assay identifies somatic mutations with high accuracy and sensitivity, providing information on single nucleotide variants, insertions/deletions (indels), amplifications, translocations, microsatellite instability (MSI) status and tumor mutation burden (TMB) to qualified healthcare professionals for use in accordance with NCCN guidelines.